drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (gene-modified autologous CAR T cells)
drug_description
Autologous, gene-modified chimeric antigen receptor T cells engineered to target both CD19 and BCMA, administered as a single IV infusion to deplete B cells, plasmablasts, and plasma cells, aiming to suppress autoantibody production and B cell–driven inflammation.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are gene-modified to express chimeric antigen receptors that recognize CD19 and BCMA. After IV infusion, CAR T cells bind CD19+ B cells and BCMA+ plasmablasts/plasma cells, become activated, and lyse these targets via cytotoxic pathways, depleting the B-lineage compartments responsible for autoantibody production and reducing B cell–driven inflammation.
drug_name
BCMA-CD19 CAR-T therapy
nct_id_drug_ref
NCT06794008